Effectiveness of melatonin for the treatment of nocturia: a randomized controlled trial
1
Issued Date
2023-02-01
Resource Type
ISSN
09373462
eISSN
14333023
Scopus ID
2-s2.0-85130259347
Pubmed ID
35596803
Journal Title
International Urogynecology Journal
Volume
34
Issue
2
Start Page
485
End Page
492
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Urogynecology Journal Vol.34 No.2 (2023) , 485-492
Suggested Citation
Leerasiri P., Pariyaeksut P., Hengrasmee P., Asumpinwong C. Effectiveness of melatonin for the treatment of nocturia: a randomized controlled trial. International Urogynecology Journal Vol.34 No.2 (2023) , 485-492. 492. doi:10.1007/s00192-022-05232-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85136
Title
Effectiveness of melatonin for the treatment of nocturia: a randomized controlled trial
Author's Affiliation
Other Contributor(s)
Abstract
Introduction and hypothesis: Nocturia affects health and quality of life (QoL). Current medical treatments can cause severe adverse effects, especially when treating elderly patients. Endogenous melatonin has a physiologic role in urinary bladder function, and the exogenous one may be beneficial for this condition. This article aims to evaluate the effectiveness and safety of melatonin for ameliorating nocturia in older women. Methods: This randomized, double-blind, placebo-controlled trial was conducted at a university hospital in Thailand. Sixty women with nocturia, aged > 55 years, were prospectively recruited and were later randomly allocated to treatment (melatonin 2 mg/day, n = 30) and control (placebo, n = 30) arms for 2 weeks. Outcome measures included nocturia episodes, nocturia-related parameters, Nocturia Quality of Life Questionnaire (N-QoL) scores, and adverse events. Results: The treatment and control groups were comparable in mean age (65.9 + 7.5 vs. 68.5 + 6.3 years). Both groups had comparable causes of nocturia with a baseline median voiding frequency of 2.3 (1.3, 6.3) and 2.3 (1.7, 5.3) episodes/night, respectively. The treatment group had significantly better outcomes than the placebo group in terms of median reduction in nocturia [-1.0 (-3.0, 0.0) vs. 0.0 (-2.3, 1.3) episodes/night; p < 0.001], increased median duration of the first uninterrupted sleep [1.0 (-0.3, 4.5) vs. 0.0 (-3.0, 2.3) h; p < 0.001], and improvement in N-QoL scoring, especially in the sleep/energy subscale (p = 0.019) and the total score (p = 0.016). Adverse events were comparable between groups. Conclusions: Melatonin can be considered a safe and effective treatment for nocturia in elderly women.